- 4-Week # shares bought: 1,500
- 4-Week # shares sold: 30,199
- 12-Week # shares bought: 1,500
- 12-Week # shares sold: 36,501
- 24-Week # shares bought: 12,500
- 24-Week # shares sold: 39,368
Chuck Grassley is hammering the privately held drug company on its $4,500 EpiPen competitor.
Impax Laboratories, Clearside Biomedical and Mylan were among the biotech stock movers in premarket trading Wednesday.
The company had a mixed fourth quarter.